{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:15:15Z","timestamp":1792080915802,"version":"4.4.0"},"reference-count":130,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In recent years, cancer treatment has been revolutionized by the introduction of many novel drugs, including immunotherapy and targeted agents, which have significantly improved the prognosis of patients with different solid tumors. While the role of traditional cytotoxic agents on fertility and reproductive health of patients with cancer is currently well established, the impact of novel treatments remains an unmet medical need and a subject of concern. Limited clinical evidence exists to date on the potential gonadotoxicity of targeted agents and immunotherapy. However, in preclinical male and female animal models, several new treatments have demonstrated the potential to affect reproductive capacity. Hence, the possible impact of these treatments on patients\u2019 reproductive potential should be urgently addressed. This work aims to review the most recent evidence regarding the gonadotoxicity of immunotherapy and novel targeted agents from the mechanisms of action of these treatments to the preclinical and clinical available data, as well as the implications on chances and risks of subsequent pregnancies. The final aim is to provide a useful tool to both physicians and patients for an informed decision-making process regarding fertility preservation and family planning before and after exposure to the new anticancer treatments.<\/jats:p>","DOI":"10.1093\/humrep\/deaf096","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T15:38:21Z","timestamp":1749310701000},"page":"1452-1466","source":"Crossref","is-referenced-by-count":27,"title":["Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-0364","authenticated-orcid":false,"given":"Luca","family":"Arecco","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova , Genova,","place":["Italy"]},{"name":"Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Academic Trials Promoting Team , Bruxelles,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4620-081X","authenticated-orcid":false,"given":"Luciana","family":"de Moura Leite","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, A.C. Camargo Cancer Center , S\u00e3o Paulo, SP,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2714-2769","authenticated-orcid":false,"given":"Gabriella","family":"Gentile","sequence":"additional","affiliation":[{"name":"Department of Radiological, Oncological and Pathological Sciences, Sapienza-University of Rome , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0530-9318","authenticated-orcid":false,"given":"Kristina","family":"Jankovic","sequence":"additional","affiliation":[{"name":"Clinic of Oncology, University Clinical Center Nis , Nis,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9368-1922","authenticated-orcid":false,"given":"Mihaela","family":"Stana","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Elysee Hospital , Alba Iulia, Alba,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5916-2449","authenticated-orcid":false,"given":"Silvia","family":"Ottonello","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4185-3436","authenticated-orcid":false,"given":"Graziana","family":"Scavone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-534X","authenticated-orcid":false,"given":"Stefano","family":"Spinaci","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Ospedale Villa Scassi ASL3 , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova , Genova,","place":["Italy"]},{"name":"Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"2025080101520348100_deaf096-B1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2025080101520348100_deaf096-B2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/humupd\/dmac004","article-title":"Anti-M\u00fcllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review","volume":"28","author":"Anderson","year":"2022","journal-title":"Hum Reprod Update"},{"key":"2025080101520348100_deaf096-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2023.14037","article-title":"Primary ovarian insufficiency associated with lenvatinib therapy in a patient with hepatocellular carcinoma: a case report","volume":"26","author":"Aoki","year":"2023","journal-title":"Oncol Lett"},{"key":"2025080101520348100_deaf096-B4","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/humrep\/deac035","article-title":"Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis","volume":"37","author":"Arecco","year":"2022","journal-title":"Hum Reprod"},{"key":"2025080101520348100_deaf096-B5","doi-asserted-by":"crossref","first-page":"102031","DOI":"10.1016\/j.esmoop.2023.102031","article-title":"Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis","volume":"8","author":"Arecco","year":"2023","journal-title":"ESMO Open"},{"key":"2025080101520348100_deaf096-B6","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41571-023-00797-4","article-title":"Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE","volume":"20","author":"Arecco","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025080101520348100_deaf096-B7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","article-title":"Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase","volume":"69","author":"Bai","year":"2020","journal-title":"Endocrine"},{"key":"2025080101520348100_deaf096-B8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025080101520348100_deaf096-B9","first-page":"2310","article-title":"Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-alpha and -beta during human testicular development and disease","volume":"87","author":"Basciani","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2025080101520348100_deaf096-B10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/17843286.2018.1476115","article-title":"Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies","volume":"74","author":"Bastin","year":"2019","journal-title":"Acta Clin Belg"},{"key":"2025080101520348100_deaf096-B11","doi-asserted-by":"crossref","first-page":"690320","DOI":"10.3389\/fonc.2021.690320","article-title":"The PREgnancy and FERtility (PREFER) study investigating the need for ovarian function and\/or fertility preservation strategies in premenopausal women with early breast cancer","volume":"11","author":"Blondeaux","year":"2021","journal-title":"Front Oncol"},{"key":"2025080101520348100_deaf096-B12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.fertnstert.2021.03.026","article-title":"Fertility preservation in men: a contemporary overview and a look toward emerging technologies","volume":"115","author":"Brannigan","year":"2021","journal-title":"Fertil Steril"},{"key":"2025080101520348100_deaf096-B13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdw696","article-title":"Immune checkpoint inhibitors-related orchitis","volume":"28","author":"Brunet-Possenti","year":"2017","journal-title":"Ann Oncol"},{"key":"2025080101520348100_deaf096-B14","doi-asserted-by":"crossref","first-page":"12013","DOI":"10.1200\/JCO.2023.41.16_suppl.12013","article-title":"Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial","volume":"41","author":"Buchbinder","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025080101520348100_deaf096-B15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/andr.12444","article-title":"Effects of the insulin-like growth factor system on testicular differentiation and function: a review of the literature","volume":"6","author":"Cannarella","year":"2018","journal-title":"Andrology"},{"key":"2025080101520348100_deaf096-B16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1530\/rep.1.00868","article-title":"Kit ligand and c-Kit are expressed during early human ovarian follicular development and their interaction is required for the survival of follicles in long-term culture","volume":"131","author":"Carlsson","year":"2006","journal-title":"Reproduction"},{"key":"2025080101520348100_deaf096-B17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"2025080101520348100_deaf096-B18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11523-017-0521-6","article-title":"Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase","volume":"12","author":"Chang","year":"2017","journal-title":"Target Oncol"},{"key":"2025080101520348100_deaf096-B19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"2025080101520348100_deaf096-B20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.semcdb.2016.01.019","article-title":"Testicular immunoregulation and spermatogenesis","volume":"59","author":"Chen","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"2025080101520348100_deaf096-B21","doi-asserted-by":"crossref","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025080101520348100_deaf096-B22","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-22-3713","article-title":"FDA Approval Summary: amivantamab for the treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"29","author":"Chon","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025080101520348100_deaf096-B23","doi-asserted-by":"crossref","first-page":"672890","DOI":"10.3389\/fcell.2021.672890","article-title":"Premature ovarian insufficiency: past, present, and future","volume":"9","author":"Chon","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2025080101520348100_deaf096-B24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMc0707841","article-title":"Primary ovarian insufficiency associated with imatinib therapy","volume":"358","author":"Christopoulos","year":"2008","journal-title":"N Engl J Med"},{"key":"2025080101520348100_deaf096-B25","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/0284186X.2018.1449251","article-title":"Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma","volume":"57","author":"Cocorocchio","year":"2018","journal-title":"Acta Oncol"},{"key":"2025080101520348100_deaf096-B26","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S1470-2045(23)00390-X","article-title":"Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement","volume":"24","author":"Cui","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025080101520348100_deaf096-B27","doi-asserted-by":"crossref","first-page":"e18089","DOI":"10.1097\/MD.0000000000018089","article-title":"Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: a CARE-compliant case report","volume":"98","author":"De Sanctis","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025080101520348100_deaf096-B28","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA Approval Summary: mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025080101520348100_deaf096-B29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1442-2042.2010.02484.x","article-title":"Male infertility in cancer patients: review of the literature","volume":"17","author":"Dohle","year":"2010","journal-title":"Int J Urol"},{"key":"2025080101520348100_deaf096-B30","doi-asserted-by":"crossref","first-page":"e1148","DOI":"10.1634\/theoncologist.2019-0094","article-title":"Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal?","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"key":"2025080101520348100_deaf096-B31","doi-asserted-by":"crossref","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE guideline: female fertility preservation","volume":"2020","author":"ESHRE Guideline Group on Female Fertility Preservation","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2025080101520348100_deaf096-B32","doi-asserted-by":"crossref","first-page":"27525","DOI":"10.1074\/jbc.M803867200","article-title":"Cross-talk between G protein-coupled and epidermal growth factor receptors regulates gonadotropin-mediated steroidogenesis in Leydig cells","volume":"283","author":"Evaul","year":"2008","journal-title":"J Biol Chem"},{"key":"2025080101520348100_deaf096-B33","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2025080101520348100_deaf096-B34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025080101520348100_deaf096-B35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br J Cancer"},{"key":"2025080101520348100_deaf096-B36","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.annonc.2022.03.076","article-title":"60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): explorative analysis in Penelope-B","volume":"33","author":"Furlanetto","year":"2022","journal-title":"Ann Oncol"},{"key":"2025080101520348100_deaf096-B37","doi-asserted-by":"crossref","first-page":"100276","DOI":"10.1016\/j.esmoop.2021.100276","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"key":"2025080101520348100_deaf096-B38","doi-asserted-by":"crossref","first-page":"102769","DOI":"10.1016\/j.ctrv.2024.102769","article-title":"Assessing risks and knowledge gaps on the impact of systemic therapies in early breast cancer on female fertility: a systematic review of the literature","volume":"128","author":"Gentile","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2025080101520348100_deaf096-B39","doi-asserted-by":"crossref","first-page":"OT1-02-03","DOI":"10.1158\/1538-7445.SABCS21-OT1-02-03","article-title":"Abstract OT1-02-03: trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05)","volume":"82","author":"Geyer","year":"2022","journal-title":"Cancer Res"},{"key":"2025080101520348100_deaf096-B40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fonc.2020.00232","article-title":"Fertility outcomes and sperm-DNA parameters in metastatic melanoma survivors receiving vemurafenib or dabrafenib therapy: case report","volume":"10","author":"Ghezzi","year":"2020","journal-title":"Front Oncol"},{"key":"2025080101520348100_deaf096-B41","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1083\/jcb.131.4.1105","article-title":"Testicular development involves the spatiotemporal control of PDGFs and PDGF receptors gene expression and action","volume":"131","author":"Gnessi","year":"1995","journal-title":"J Cell Biol"},{"key":"2025080101520348100_deaf096-B42","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025080101520348100_deaf096-B43","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/biomedicines10030655","article-title":"Assessing the future of solid tumor immunotherapy","volume":"10","author":"Guha","year":"2022","journal-title":"Biomedicines"},{"key":"2025080101520348100_deaf096-B44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"2025080101520348100_deaf096-B45","doi-asserted-by":"crossref","first-page":"TPS631","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS631","article-title":"Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-\/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV","volume":"42","author":"Harbeck","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025080101520348100_deaf096-B46","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1002\/cncr.31732","article-title":"Pregnancy after cancer: does timing of conception affect infant health?","volume":"124","author":"Hartnett","year":"2018","journal-title":"Cancer"},{"key":"2025080101520348100_deaf096-B47","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3390\/life13051209","article-title":"The impact of systemic oncological treatments on the fertility of adolescents and young adults\u2014a systematic review","volume":"13","author":"Himpe","year":"2023","journal-title":"Life"},{"key":"2025080101520348100_deaf096-B48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/gb-2005-6-2-209","article-title":"The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease","volume":"6","author":"Holmes","year":"2005","journal-title":"Genome Biol"},{"key":"2025080101520348100_deaf096-B49","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3892\/mco.2017.1237","article-title":"Ovarian function following targeted anti-angiogenic therapy with bevacizumab","volume":"6","author":"Imai","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"2025080101520348100_deaf096-B50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025080101520348100_deaf096-B51","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1210\/en.2014-1341","article-title":"ROS1 signaling regulates epithelial differentiation in the epididymis","volume":"155","author":"Jun","year":"2014","journal-title":"Endocrinology"},{"key":"2025080101520348100_deaf096-B52","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.fertnstert.2020.01.002","article-title":"New insights to guide patient care: the bidirectional relationship between male infertility and male health","volume":"113","author":"Kasman","year":"2020","journal-title":"Fertil Steril"},{"key":"2025080101520348100_deaf096-B53","first-page":"e63592","article-title":"Anaplastic lymphoma kinase-tyrosine kinase inhibitor treatment for metastatic non-small cell lung cancer throughout the entire gestation period","volume":"16","author":"Kato","year":"2024","journal-title":"Cureus"},{"key":"2025080101520348100_deaf096-B54","doi-asserted-by":"crossref","first-page":"e2100153","DOI":"10.1200\/GO.21.00153","article-title":"Knowledge, practice, and attitudes of physicians in low- and middle-income countries on fertility and pregnancy-related issues in young women with breast cancer","volume":"8","author":"Khan","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"2025080101520348100_deaf096-B55","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/OP.22.00469","article-title":"Minding the bathwater: fertility and reproductive toxicity in the age of immuno-oncology","volume":"18","author":"Kim","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2025080101520348100_deaf096-B56","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/tcmj.tcmj_255_19","article-title":"Role of hypothyroidism and associated pathways in pregnancy and infertility: clinical insights","volume":"32","author":"Koyyada","year":"2020","journal-title":"Tzu Chi Med J"},{"key":"2025080101520348100_deaf096-B57","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1074\/jbc.M109.085845","article-title":"Inhibition of Ser\/Thr phosphatases induces capacitation-associated signaling in the presence of Src kinase inhibitors","volume":"285","author":"Krapf","year":"2010","journal-title":"J Biol Chem"},{"key":"2025080101520348100_deaf096-B58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.theriogenology.2018.12.019","article-title":"FMS-like tyrosine kinase 3 is a key factor of male fertility","volume":"126","author":"Kwon","year":"2019","journal-title":"Theriogenology"},{"key":"2025080101520348100_deaf096-B59","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025080101520348100_deaf096-B60","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jnci\/djy094","article-title":"Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients","volume":"111","author":"Lambertini","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025080101520348100_deaf096-B61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.6004\/jnccn.2022.7065","article-title":"Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer","volume":"21","author":"Lambertini","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"2025080101520348100_deaf096-B62","doi-asserted-by":"crossref","first-page":"e13779","DOI":"10.1111\/eci.13779","article-title":"Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue","volume":"52","author":"Lambertini","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"2025080101520348100_deaf096-B63","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","article-title":"Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient\u2013level data","volume":"36","author":"Lambertini","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025080101520348100_deaf096-B64","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann Oncol"},{"key":"2025080101520348100_deaf096-B65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"2025080101520348100_deaf096-B66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cpt.2023.11.005","article-title":"Common endocrine system adverse events associated with immune checkpoint inhibitors","volume":"2","author":"Li","year":"2024","journal-title":"Cancer Pathog Ther"},{"key":"2025080101520348100_deaf096-B67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2025080101520348100_deaf096-B68","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1158\/1078-0432.CCR-23-3738","article-title":"FDA Approval Summary: enfortumab vedotin plus pembrolizumab for cisplatin-ineligible locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Maguire","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025080101520348100_deaf096-B69","first-page":"341","article-title":"Comparing the gonadotoxicity of multiple breast cancer regimens: important understanding for managing breast cancer in pre-menopausal women","volume":"13","author":"Martelli","year":"2021","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2025080101520348100_deaf096-B70","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/humrep\/dez108","article-title":"Beyond fertility preservation: role of the oncofertility unit in the reproductive and gynecological follow-up of young cancer patients","volume":"34","author":"Massarotti","year":"2019","journal-title":"Hum Reprod"},{"key":"2025080101520348100_deaf096-B71","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/humupd\/5.5.535","article-title":"Stem cell factor\/c-kit system in spermatogenesis","volume":"5","author":"Mauduit","year":"1999","journal-title":"Hum Reprod Update"},{"key":"2025080101520348100_deaf096-B72","doi-asserted-by":"crossref","first-page":"102673","DOI":"10.1016\/j.jogoh.2023.102673","article-title":"Second-trimester medical abortion after exposure to lorlatinib during early pregnancy, a case report","volume":"52","author":"Mawet","year":"2023","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2025080101520348100_deaf096-B73","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/EDBK_175631","article-title":"Novel targeted agents and immunotherapy in breast cancer","volume":"37","author":"Mayer","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"2025080101520348100_deaf096-B74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025080101520348100_deaf096-B75","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imm.13136","article-title":"Immune responses in the human female reproductive tract","volume":"160","author":"Monin","year":"2020","journal-title":"Immunology"},{"key":"2025080101520348100_deaf096-B76","first-page":"4197","article-title":"Raf-1 protein kinase is important for progesterone-induced Xenopus oocyte maturation and acts downstream of mos","volume":"13","author":"Muslin","year":"1993","journal-title":"Mol Cell Biol"},{"key":"2025080101520348100_deaf096-B77","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/iju.14646","article-title":"Effect of tyrosine kinase inhibitors and immune checkpoint inhibitors on spermatogenesis in humans","volume":"28","author":"Nagamitsu","year":"2021","journal-title":"Int J Urol"},{"key":"2025080101520348100_deaf096-B78","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"FDA Approval Summary: fam-trastuzumab deruxtecan-Nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025080101520348100_deaf096-B79","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.4049\/jimmunol.174.10.6161","article-title":"Testicular immune privilege promotes transplantation tolerance by altering the balance between memory and regulatory T cells","volume":"174","author":"Nasr","year":"2005","journal-title":"J Immunol"},{"key":"2025080101520348100_deaf096-B80","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"2025080101520348100_deaf096-B81","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.fertnstert.2022.03.004","article-title":"A comparison of fertility preservation outcomes in patients who froze oocytes, embryos, or ovarian tissue for medically indicated circumstances: a systematic review and meta-analysis","volume":"117","author":"N\u00ed Dhonnabh\u00e1in","year":"2022","journal-title":"Fertil Steril"},{"key":"2025080101520348100_deaf096-B82","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1530\/rep.1.00978","article-title":"Platelet-derived growth factor modulates the primordial to primary follicle transition","volume":"131","author":"Nilsson","year":"2006","journal-title":"Reproduction"},{"key":"2025080101520348100_deaf096-B83","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/sj.bjc.6602585","article-title":"Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients","volume":"92","author":"Nishio","year":"2005","journal-title":"Br J Cancer"},{"key":"2025080101520348100_deaf096-B84","doi-asserted-by":"crossref","first-page":"25842","DOI":"10.1074\/jbc.M703474200","article-title":"Glial cell line-derived neurotrophic factor regulation of genes essential for self-renewal of mouse spermatogonial stem cells is dependent on Src family kinase signaling","volume":"282","author":"Oatley","year":"2007","journal-title":"J Biol Chem"},{"key":"2025080101520348100_deaf096-B85","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025080101520348100_deaf096-B86","doi-asserted-by":"crossref","first-page":"e002220","DOI":"10.1136\/jitc-2020-002220","article-title":"Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology","volume":"9","author":"\u00d6zdemir","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025080101520348100_deaf096-B87","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"2025080101520348100_deaf096-B89","doi-asserted-by":"crossref","first-page":"e000771","DOI":"10.1136\/esmoopen-2020-000771","article-title":"Gender-specific aspects related to type of fertility preservation strategies and access to fertility care","volume":"5","author":"Perachino","year":"2020","journal-title":"ESMO Open"},{"key":"2025080101520348100_deaf096-B90","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0000000000000599","article-title":"Update on pregnancy following breast cancer diagnosis and treatment","volume":"28","author":"Perachino","year":"2022","journal-title":"Cancer J Sudbury Mass"},{"key":"2025080101520348100_deaf096-B91","doi-asserted-by":"crossref","first-page":"199","DOI":"10.18632\/oncotarget.27876","article-title":"Testosterone deficiency in men receiving immunotherapy for malignant melanoma","volume":"12","author":"Peters","year":"2021","journal-title":"Oncotarget"},{"key":"2025080101520348100_deaf096-B92","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2025080101520348100_deaf096-B93","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1634\/theoncologist.2018-0722","article-title":"Severe epididymo-orchitis and encephalitis complicating anti-PD-1 therapy","volume":"24","author":"Quach","year":"2019","journal-title":"Oncologist"},{"key":"2025080101520348100_deaf096-B94","first-page":"101488","article-title":"Onset of azoospermia in man treated with ipilimumab\/nivolumab for BRAF negative metastatic melanoma","volume":"34","author":"Rabinowitz","year":"2021","journal-title":"Urol Case Rep"},{"key":"2025080101520348100_deaf096-B95","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025080101520348100_deaf096-B96","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s10815-021-02181-6","article-title":"Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review","volume":"38","author":"Rambhatla","year":"2021","journal-title":"J Assist Reprod Genet"},{"key":"2025080101520348100_deaf096-B97","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1530\/RAF-22-0020","article-title":"Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies","volume":"3","author":"Rosario","year":"2022","journal-title":"Reprod Fertil"},{"key":"2025080101520348100_deaf096-B98","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10549-015-3426-z","article-title":"Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial)","volume":"151","author":"Ruddy","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2025080101520348100_deaf096-B99","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/jnci\/djaa160","article-title":"Antimullerian hormone as a serum biomarker for risk of chemotherapy-induced amenorrhea","volume":"113","author":"Ruddy","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025080101520348100_deaf096-B100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-021-06267-8","article-title":"Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)","volume":"189","author":"Ruddy","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2025080101520348100_deaf096-B101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2021.04.031","article-title":"Male fertility during and after immune checkpoint inhibitor therapy: a cross-sectional pilot study","volume":"152","author":"Salzmann","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025080101520348100_deaf096-B102","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12094-021-02699-2","article-title":"Multidisciplinary consensus on the criteria for fertility preservation in cancer patients","volume":"24","author":"Santaballa","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"2025080101520348100_deaf096-B103","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/COC.0b013e3182a46896","article-title":"Multiple endocrine disruption by the MET\/ALK inhibitor crizotinib in patients with non-small cell lung cancer","volume":"38","author":"Sargis","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"2025080101520348100_deaf096-B104","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.3390\/cancers15204923","article-title":"The role of cyclin-dependent kinases (CDK) 4\/6 in the ovarian tissue and the possible effects of their exogenous inhibition","volume":"15","author":"Scavone","year":"2023","journal-title":"Cancers"},{"key":"2025080101520348100_deaf096-B105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cytogfr.2008.01.003","article-title":"The epidermal growth factor receptor and its ligands in female reproduction: insights from rodent models","volume":"19","author":"Schneider","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025080101520348100_deaf096-B106","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaoncol.2020.1641","article-title":"Association of impaired spermatogenesis with the use of immune checkpoint inhibitors in patients with metastatic melanoma","volume":"6","author":"Scovell","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025080101520348100_deaf096-B107","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome","volume":"351","author":"Seshadri","year":"2004","journal-title":"N Engl J Med"},{"key":"2025080101520348100_deaf096-B108","doi-asserted-by":"crossref","first-page":"648141","DOI":"10.3389\/fendo.2021.648141","article-title":"The molecular mechanism of sex hormones on Sertoli cell development and proliferation","volume":"12","author":"Shah","year":"2021","journal-title":"Front Endocrinol"},{"key":"2025080101520348100_deaf096-B109","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yexcr.2007.06.025","article-title":"A co-culture system reveals the involvement of intercellular pathways as mediators of the lutropin receptor (LHR)-stimulated ERK1\/2 phosphorylation in Leydig cells","volume":"314","author":"Shiraishi","year":"2008","journal-title":"Exp Cell Res"},{"key":"2025080101520348100_deaf096-B110","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"2025080101520348100_deaf096-B111","doi-asserted-by":"crossref","first-page":"1108124","DOI":"10.3389\/fonc.2023.1108124","article-title":"Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer","volume":"13","author":"Soberanis Pina","year":"2023","journal-title":"Front Oncol"},{"key":"2025080101520348100_deaf096-B112","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.fertnstert.2016.08.011","article-title":"Ovarian stimulation in young adult cancer survivors on targeted cancer therapies","volume":"106","author":"Su","year":"2016","journal-title":"Fertil Steril"},{"key":"2025080101520348100_deaf096-B113","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025080101520348100_deaf096-B114","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025080101520348100_deaf096-B115","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/cen.13577","article-title":"Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B","volume":"88","author":"Thomas","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025080101520348100_deaf096-B116","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary","volume":"18","author":"Thornton","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025080101520348100_deaf096-B117","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-22-0057","article-title":"Preclinical characterization of relatlimab, a human lag-3-blocking antibody, alone or in combination with nivolumab","volume":"10","author":"Thudium","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025080101520348100_deaf096-B118","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/humupd\/dmz043","article-title":"BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging","volume":"26","author":"Turan","year":"2020","journal-title":"Hum Reprod Update"},{"key":"2025080101520348100_deaf096-B119","author":"U.S. Food and Drug Administration","year":"2021"},{"key":"2025080101520348100_deaf096-B120","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"2025080101520348100_deaf096-B121","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/cncr.35293","article-title":"Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced non-small cell lung cancer","volume":"130","author":"Vita","year":"2024","journal-title":"Cancer"},{"key":"2025080101520348100_deaf096-B122","doi-asserted-by":"crossref","first-page":"410","DOI":"10.21873\/invivo.13093","article-title":"Gonadal function in male patients with metastatic renal cell cancer treated with sunitinib","volume":"37","author":"Volta","year":"2023","journal-title":"In Vivo"},{"key":"2025080101520348100_deaf096-B123","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-20-3119","article-title":"FDA Approval Summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer","volume":"27","author":"Wahby","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025080101520348100_deaf096-B124","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025080101520348100_deaf096-B125","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1158\/1078-0432.CCR-19-3980","article-title":"FDA Approval Summary: ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer","volume":"26","author":"Wedam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025080101520348100_deaf096-B126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","article-title":"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice","volume":"3","author":"Winship","year":"2022","journal-title":"Nat Cancer"},{"key":"2025080101520348100_deaf096-B127","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/humrep\/deaa128","article-title":"The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation","volume":"35","author":"Winship","year":"2020","journal-title":"Hum Reprod"},{"key":"2025080101520348100_deaf096-B128","doi-asserted-by":"crossref","first-page":"e0123542","DOI":"10.1371\/journal.pone.0123542","article-title":"Targeted disruption of ALK reveals a potential role in hypogonadotropic hypogonadism","volume":"10","author":"Witek","year":"2015","journal-title":"PLoS One"},{"key":"2025080101520348100_deaf096-B129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-21-0209","article-title":"Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse","volume":"252","author":"Xu","year":"2021","journal-title":"J Endocrinol"},{"key":"2025080101520348100_deaf096-B130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-014-2914-x","article-title":"What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis","volume":"145","author":"Zhao","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2025080101520348100_deaf096-B131","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/40\/8\/1452\/63450087\/deaf096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/40\/8\/1452\/63450087\/deaf096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:52:44Z","timestamp":1754027564000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/40\/8\/1452\/8158278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":130,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,6,7]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deaf096","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,6,7]]}}}